Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

COMMENTED

Immunotherapy

Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy

★ 3 Recommended and commented by Prof. Dr Dr Sacha Rothschild, Faculty Member

Eur J Cancer

Ghisoni E, Wicky A, Bouchaab H, Imbimbo M, Delyon J, Gautron Moura B, Gérard CL, Latifyan S, Özdemir BC, Caikovski M, Pradervand S, Tavazzi E, Gatta R, Marandino L, Valabrega G, Aglietta M, Obeid M, Homicsko K, Mederos Alfonso NN, Zimmermann S, Coukos G, Peters S, Cuendet MA, Di Maio M, Michielin O

doi: 10.1016/j.ejca.2021.03.010

Melanoma and Skin Cancer

C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting

Melanoma Res

Lauwyck J, Beckwée A, Santens A, Schwarze JK, Awada G, Vandersleyen V, Aspeslagh S, Neyns B

doi: 10.1097/CMR.0000000000000748

Further Publications Dermatology

Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune checkpoint inhibitors: A United States population-level analysis

J Am Acad Dermatol

Wongvibulsin S, Pahalyants V, Kalinich M, Murphy W, Yu KH, Wang F, Chen ST, Reynolds K, Kwatra SG, Semenov YR

doi: 10.1016/j.jaad.2021.03.094

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

Rheumatological complications of immune checkpoint inhibitor therapy

Rev Med Suisse.

Lazarou I, Fernandez E

doi: undefined.

T Cells

Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer

J Autoimmun

Calabrese LH, Caporali R, Blank CU, Kirk AD

doi: 10.1016/j.jaut.2020.102546

Further Publications Rheumatology

Predictors of rheumatic immune-related adverse events and de novo inflammatory arthritis after immune checkpoint inhibitor treatment for cancer

Arthritis Rheumatol

Cunningham-Bussel A, Wang J, Prisco LC, Martin LW, Vanni KMM, Zaccardelli A, Nasrallah M, Gedmintas L, MacFarlane LA, Shadick NA, Awad MM, Rahma O, LeBoeuf NR, Gravallese EM, Sparks JA

doi: 10.1002/art.41949

Further Publications DermatologyFurther Publications ImmunologyFurther Publications Rheumatology

An MRI study of immune checkpoint inhibitor-induced musculoskeletal manifestations myofasciitis is the prominent imaging finding

Rheumatology (Oxford).

Daoussis D, Kraniotis P, Filippopoulou A, Argiriadi R, Theodoraki S, Makatsoris T, Koutras A, Kehagias I, Papachristou DJ, Solomou A, Kalofonos H, Liossis SN

doi: 10.1093/rheumatology/kez361.

Immunomodulation

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Eur J Cancer

Buti S, Bersanelli M, Perrone F, Tiseo M, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, Spagnolo F, Rastelli F, Pergolesi F, Santini D, Russano M, Anesi C, Giusti R, Filetti M, Marchetti P, Botticelli A, Gelibter A, Occhipinti MA, Ferrari M, Vitale MG, Nicolardi L, Chiari R, Rijavec E, Nigro O, Tuzi A, De Tursi M, Di Marino P, Conforti F, Queirolo P, Bracarda S, Macrini S, Gori S, Zoratto F, Veltri E, Di Cocco B, Mallardo D, Vitale MG, Santoni M, Patruno L, Porzio G, Ficorella C, Pinato DJ, Ascierto PA, Cortellini A

doi: 10.1016/j.ejca.2020.09.033

Immunotherapy

Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma

Cancer.

Wisdom AJ, Mowery YM, Riedel RF, Kirsch DG

doi: 10.1002/cncr.31517.

Related content